Obermatt
See Similar Stocks →

Anixa Biosciences

NAQ:ANIX · US03528H1095
BiotechnologyX-Small

360° View

no current rank
Price/Sales—
Price/Earnings68
Price/Book7
Dividend Yield—
Revenue Growth—
Profit Growth17
Capital Growth8
TSR 52w22
Leverage85
Liquidity61
Refinancing81
Combined—
Analyst Opinions51
Pro Holdings9
Opinion Changes5
Market Pulse39

Profile

CountryUSA
IndustryBiotechnology
SizeX-Small
TypePublic Company
ExchangeNASDAQCM
Founded1982
Employees6
Websiteanixa.com
ISINUS03528H1095
Last UpdateApr 2, 2026
Index & Theme
ImmunologyOncologyVaccinesBiotechnologyFinanceMarket ResearchPharmaceuticalTherapeutics

Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that focuses on critical unmet needs in oncology. The company's therapeutics program comprises the development of liraltagene autoleucel (lira-cel), a chimeric endocri…

Similar Stocks

The companies this stock is ranked against.

Compare Anixa Biosciences with its peers
Atossa Therapeutics
NAQ:ATOS
45
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Greenwich Lifesciences
NAQ:GLSI
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Elicio Therapeutics
NAQ:ELTX
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Legend Biotech
NSQ:LEGN
30
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Aktis Oncology
NSQ:AKTS
28
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Immunitybio
NSQ:IBRX
19
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →